Yinnuo Pharmaceutical-B (02591) announced interim results, with a loss of 115 million yuan to the mother narrowing by 5.72% year-on-year

Zhitongcaijing · 4d ago

According to the Zhitong Finance App, Yinnuo Pharmaceutical-B (02591) announced interim results for the six months ended June 30, 2026. The group obtained revenue of RMB 782.18 million (same unit), an increase of 38.57% over the previous year; loss attributable to the owner of the parent company was 115 million yuan, a decrease of 5.72% year on year; loss per share was 0.25 yuan.

According to the announcement, the group commercialized esupaglutide α for the treatment of T2D in mainland China in February 2025 and in Macau, China in September 2025. Since it was included in the national medical insurance drug list for the treatment of adult T2D in December 2025 (effective from January 1, 2026), esupaglutide α continued to gain market coverage and commercial momentum.